

1 Personalized External Aortic Root Support in Aneurysm Disease

2

3 Tom Treasure*

4 Professor of Cardiothoracic Surgery

5 University College London

6 London, UK

7

8 Conal Austin

9 Consultant Cardiac Surgeon

10 St Thomas' Hospital

11 London, UK

12

13 Louise Amelia Kenny

14 Cardiac surgeon

15 Waikato District Health Board

16 New Zealand

17

18 John Pepper

19 Professor of Cardiac Surgery

20 NIHR Imperial Biomedical Research Centre and the Royal Brompton Hospital

21 London, UK

22

23 National Heart and Lung Institute, Imperial College, London

24

25 NIHR Imperial Biomedical Research Centre

26

27

28 *corresponding author tom.treasure@gmail.com

29

30

31

32

33 In the last year CA has been reimbursed by the manufacturing company Exstent
34 Limited for travelling expenses to proctor surgeons. Prior to that, as with the other
35 authors TT and JRP, we have covered all our own expenses without the support of
36 the company which was a self-funding start up.

37

38

39 Key points:

- 40 • The adoption of PEARS has increased to 30 centres 12 countries.
- 41 • By August 2022 there were 582 PEARS operations for aortic root aneurysms
42 with one peri-operative death.
- 43 • There have been no aortic dissection in the supported ascending aorta.

44

45

46

47 Structured abstract <200 words [195]

48 *Purpose of review:*

49 To bring together and annotate publications about personalised external aortic root
50 support reported in the 18 months preceding submission.

51

52 *Recent findings:*

53 The total number of PEARS operations is now approaching 700 in 30 centres in
54 Australia, Belgium, Brazil, Czech Republic, Great Britain, Greece, Ireland, Malaysia,
55 Netherlands, New Zealand, Poland and Slovakia. There are continued reports of stability
56 of aortic dimensions and aortic valve function with the only exceptions known being
57 where the surgeon has deviated from the instructions for use of the device. The median
58 root diameter of Marfan patients having PEARS was 47 mm suggesting that the existing
59 criterion of 50 mm is due for reconsideration. The peri-operative mortality in the first
60 200 patients was 0.5% and is currently estimated to be less than 0.3%. The first
61 recipient remains alive and well after 18 years. The use of PEARS as an adjunct to the
62 Ross operation to support the pulmonary autograft is being explored in several centres.

63

64 *Summary:*

65 The operation requires proctoring and adherence to a strict operative protocol and with
66 those precautions excellent results are attained. The evidence and opinions provided in
67 the cited publications indicate that PEARS is a proven and successful prophylactic
68 operation for aortic root aneurysm.

69

70

71 *Keywords: 3-5*

72 Aortic root aneurysm; aortopathy; external support

73

74

75

76

77

78

79 Text <2000 1793 Words

80

81 *Introduction:*

82 The scope of this review is very precisely defined by its title. Personalised external
83 aortic root support (PEARS) was first proposed at a meeting of the British Marfan
84 Association in 2000 at St George's Hospital London by its inventor, Taliesin
85 Goleworthy, a design engineer with inherited Marfan syndrome. The proposal was
86 followed by careful analysis of the anatomy, possible materials, surgical feasibility,
87 imaging requirements and manufacture. This included software development to enable
88 computer assisted design (CAD) modelling and rapid prototyping, now commonly
89 known as 3-D printing. The "first in man" operation was reported in The Lancet as a
90 Research Letter in 2004.(1)

91

92 PEARS is "external" and acts as a "support" rather than as a replacement of the
93 ascending aorta. It has two unique features which distinguish it from all other described
94 techniques.

95

- 96 1. It is “personalised” in the sense that it is manufactured to replicate the patient’s
97 own aorta with three dimensional spatial data obtained from digital imaging.
98 This makes it quite distinct from the *ad hoc* intra-operative tailoring of graft
99 material to support the ascending aorta. This may be with or without that is
100 surgical excision of part of the aorta —aortoplasty — to reduce its
101 circumference.(2-6)
102 2. The external support because incorporated to effectively form a neo-aorta. This
103 is because instead of stiff low porosity vascular graft material, a soft pliant
104 macroporous mesh with 0.7 mm pore size is used. Incorporation has been shown
105 histologically in sheep implants and confirmed in man.(7, 8)

106
107 PEARS along with the David(9) and Florida sleeve(4, 5) are operations sparing of the
108 aortic valve. It differs from them in that it requires preoperative manufacture of the
109 implant. That effectively precludes its use in an emergency situation within the
110 currently existing operative procedures in which “made-to-measure” is a key
111 component. PEARS does not fit with *ad hoc* decision making. That is important in
112 follow-up evaluation of clinical outcome because for other techniques the eventual
113 decision of whether to conserve or replace the aortic valve can be made while the
114 operation is in progress making “intention to treat” analysis undeliverable.

115
116 An important conceptual feature of PEARS is that the surgeon is provided with an
117 engineered product and in the words of David Pye, furniture designer and academic, it
118 replaces the “workmanship of risk” with the “workmanship of certainty”.(10) Skilled
119 and experienced surgeons pride themselves in their ability to improvise and innovate as
120 do artists and craftsmen but with that goes the possibility of error and bad judgement.
121 The PEARS Instructions for Use(11) have only changed in two details since the first
122 operation. With faster acquisition and lower radiation doses, computerised tomography
123 (CT) can now be used instead of cardiac magnetic resonance imaging (cMRI). Rather
124 than cutting a hole in the mesh for the coronary artery a star shape opening — or
125 asterisk — is recommended, formed by three intersecting cuts each of the same length
126 as the external diameter of the coronary artery as shown in Figure 3.(11, 12)

127
128 Stepwise evaluation by the team evaluating PEARS confirmed that it held the aortic size
129 over time and an undersized device could reduce the aortic size without crimping the
130 wall or altering its morphology.(13) In a matched pair analysis it reduced operative
131 time, it avoided or greatly reduced time of cardiopulmonary bypass and obviated the
132 routine need for blood products.(14)

133
134 PEARS was used relatively early in our experience to safeguard a patient whose aorta
135 had dilated during her first pregnancy.(15) We know of ten patients who have had
136 PEARS with eleven subsequent successful pregnancies without evidence of further
137 aortic dilatation. All are well. One of these patients had her (off-pump) PEARS surgery
138 during her 2nd trimester.(18)

139
140 The use of a PEARS device to stabilise the neo-aorta in the Ross pulmonary autograft
141 procedure has been proposed and was discussed in an Expert Review of Medical
142 Devices(16) but it was not mentioned in an excellent review in Current Opinion in
143 Cardiology 2022 which considered various method of supporting the pulmonary
144 autograft after the Ross operation.(17) The omission is assumed to be because the

145 editors' instructions require references to published work in the previous 18 months. In
146 an extension of the principle, PEARS supported pulmonary autografts for Ross
147 operations, have been used in 69 patients.(18) At the time of writing the results are not
148 yet published.

149
150

151 **Review:**

152 Literature searches for related publication in the 18 months up to the end of March
153 2022 discovered nine publications related to personalised aortic root support. For the
154 purposes of the discussion we will summarise them under five headings.

155

156 **Data on patient numbers, the case mix and outcomes**

157 Because the device is only available from one manufacturer complete data are available
158 as to how many operations have been done, at which centres, and the nature of the
159 cases operated on.(18) On 17th January 2022 a total 570 patients have been treated,
160 392(69%) with various categories of congenitally determined aortic disease and the
161 largest single pathological group — 274(48%) — are people with Marfan syndrome.

162

163 Patients from 1 to 317 who had operation at 25 surgical centres were the basis of a
164 clinical report published in September 2020.(19) The most complete and detailed
165 clinical reports was published by the originators and early adopters of PEARS. This
166 includes the first 200 consecutive patients with follow-up of at least a year and a total
167 753 postoperative years.(20) There was one new type B dissection which was
168 asymptomatic and discovered on imaging three years postoperatively. There were no
169 device related aortic events. Of these 200 patients 48 had aortic valve regurgitation
170 prior to their PEARS procedure, 42 grade 1/4 and 6 grade 2/4. Regurgitation was
171 abolished in 30 and reduced or abolished in all but one of the grade 2 patients.
172 Increasingly supports of 95% modelled size are used and there is a likelihood that this
173 will further reduce residual aortic regurgitation.(20)

174

175 The report on the first 200 patients was accompanied by an Editorial which was
176 unreserved in its recognition of the PEARS record:

177

178 "The results published by Van Hoof and colleagues are nothing short of
179 remarkable, considering some of the technical challenges of isolation of the
180 coronary arteries and dissection to the level of the ventriculoaortic junction. This
181 is especially true in the context of CPB use being limited in this series. If nothing
182 else, this is an incredible display of surgical skill and technical evolution."(21)

183

184 Of course it follows that recognition of the level of surgical skill required to attaining
185 such results also raised doubts about its general applicability. However its advantages
186 in reducing the magnitude of surgery and potentially optimal and durable conservation
187 of the aortic valve it can be used at an earlier stage in the progression of aortopathy and
188 spare patients potentially years of anxiety and years of attempted medical treatment
189 aimed at slowing the rate of progression.(22)

190

191 **1.The technical challenge of the operation**

192 Two papers are about the operative technique. One was from the authors of the 317
193 patient follow up study. Only a few of these patients were operated on by themselves

194 but the process of reviewing the results prompted a technical paper about PEARS —
195 “how to implant it” — which should be required reading for any surgeons embarking on
196 a PEARS programme.(12) The illustrations provided by Kenny et al are superb.(23)
197 Figures 1, 2, 3

198
199 A third paper is very clearly about how not to do it.(24) There was an inadvertent
200 “proof of concept” experiment. The surgeon had decided against completing the
201 operation according to the manufacturer’s instructions for use(23) and instead of
202 dissecting the aorta down to the aorto-ventricular junction, he cut the personalised
203 sleeve and discarded the portion intended to support the sub coronary root. The
204 unsupported aorta progressively dilated in that segment and aortic valve regurgitation
205 ensued. The cause was discovered at a rescue operation some years later and
206 rectified.(24)

207

208 **2.The relative merits of PEARS and an ad hoc wrap**

209 It is interesting that Burke and Bavaria, praising the skill of the PEARS surgeons
210 somewhat down played the benefits of this approach writing

211

212 “Despite the PEARS procedure being a novel and potentially disruptive surgical
213 technique to address aortic root dilation, the concept of aortic aneurysm
214 ‘wrapping’ is not entirely new and has undergone several iterations in the past.
215 The first report of aneurysm wrapping of the ascending aorta was published by
216 Francis Robicsek in 1982.”(3)

217

218 During the time frame of the search there was a publication reporting results for
219 wrapping in the Robicsek style.(25) Aortic surgeons had not persisted with the method
220 due to patterns of failure and indeed PEARS was predicted by some to be destined to fail
221 in similar ways but the soft pliant porous nature of the device had not been appreciated.
222 The paper was contradicted by Van Hoof of the Leuven group pointing to the evidence
223 within the paper that ad-hoc wrapping with stiff low-porosity material designed for a
224 quite different application remains unsatisfactory.(26)

225

226

227 **3.The feasibility of a randomised controlled trial**

228 The call for a controlled trial has been a recurrent theme in the progress of PEARS and
229 was carefully considered at various points. A paper from Nienaber and colleagues
230 carefully examined the issues.

231

232 “A procedure probably most usefully applied early in the process of progressive
233 dilation (such as PEARS) would be compared to an established operation
234 intended for later in the dilation process, i.e., when reaching a critical threshold
235 for replacement surgery (such as the David and Yacoub procedures). In other
236 words, it would be comparing PEARS with apples, certainly not scientifically
237 sound for randomization.”(27)

238

239 **5.PEARS as an adjunct to the Ross procedure**

240 Although there are no published data on the Ross PEARS with 69 operations already
241 done we can expect them.(18) The paper from the Leuven group is the product of a very
242 fruitful collaboration and is an outstanding contribution on the concept.(28)

243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276

Conclusion:

It is 18 years since the first PEARS operation and numbers accrued very slowly during the first 10 years. The data are now being published and seem to be well received but the valve sparing root replacement is widely accepted and is being delivered at low risk. The continued collection and reporting of outcomes is going to be essential if PEARS is to be recognised as offering durable results at low risk.

One aspect that remains a concern for patients is the deliberate watch and wait for young patients for whom an operation is eventually going to be advised. The safer the operation the less justified is the wait and it is a more realistic balancing of benefits versus risk for early intervention which PEARS offers. What has been shown is that people ascribe quite different values to postponement to put off risk and earlier acceptance of risk to curtail the years of anxiety.(22) It is an area for collaborative work with patients and other advocated rather than a clinical guideline developed by clinician consensus.

Acknowledgements:


1. Acknowledgements: Professor Robert Anderson was an adviser to the project from the outset. Professor Raad Mohiaddin has provided expertise in cardiac magnetic resonance imaging from early in the development work.

2. Financial support and sponsorship: The authors have received no funding or grant support either for writing this Current Opinion article or for their involvement in the external support project.

3. Conflicts of interest: none


277
278
279

Figure titles and legends




280
281
282
283
284
285
286
287

Figure 1. A right-angled forceps is introduced below the right coronary artery and a plane is created between it and the aneurysm. [A] This plane is deepened using a combination of blunt and sharp dissection the level of the ventriculo-aortic junction below the convexity of the right coronary sinus. The PEARs former is helpful in determining completeness dissection. (Illustration from Kenny et al)(23)



288

289 Figure 2. [A] The aorta is retracted cranially to the right using a retraction suture. [B]
290 The pulmonary artery is retracted cranially and to the left with a malleable retractor.
291 [C] The plane between the root of the pulmonary artery and the left coronary sinus is
292 dissected using the same blunt and sharp combination until the left coronary artery
293 comes into view. A right angled forceps is then used to gently dissect the tissue between
294 the coronary artery and the aortic wall. [D] Once space is created between the left main
295 coronary artery. (Illustration from Kenny et al)(23)
296



297
 298 Figure 3. [A] Making the asterisk shaped incisions for the exit of the coronary arteries.
 299 [B] The chain stitch is released to open out the device. [C] Radial incisions are made to
 300 the openings for the coronary arteries thus fashioning the tabs to pass beneath the
 301 arteries. (Illustration from Kenny et al)(23)
 302

303

304

305

306

307 Reference section:

- 308 1. Golesworthy T, Lamperth M, Mohiaddin R, Pepper J, Thornton W, Treasure T. A
309 jacket for the Marfan's aorta. *Lancet*. 2004;364(9445):1582.
310
- 311 2. Robicsek F, Thubrikar MJ. Conservative operation in the management of annular
312 dilatation and ascending aortic aneurysm. *Ann Thorac Surg*. 1994;57(6):1672-4.
313
- 314 3. Robicsek F. A new method to treat fusiform aneurysms of the ascending aorta
315 associated with aortic valve disease: an alternative to radical resection. *Ann Thorac*
316 *Surg*. 1982;34(1):92-4.
317
- 318 4. Hess PJ, Jr., Klodell CT, Beaver TM, Martin TD. The Florida sleeve: a new
319 technique for aortic root remodeling with preservation of the aortic valve and sinuses.
320 *Ann Thorac Surg*. 2005;80(2):748-50.
321
- 322 5. Volguina IV, Miller DC, Lemaire SA, Palmero LC, Wang XL, Connolly HM, et al.
323 Valve-sparing and valve-replacing techniques for aortic root replacement in patients
324 with Marfan syndrome: analysis of early outcome. *J Thorac Cardiovasc Surg*.
325 2009;137(3):641-9.
326
- 327 6. Plonek T, Dumanski A, Obremaska M, Kustrzycki W. First beating-heart valve-
328 sparing aortic root repair: a "corset" technique. *Ann Thorac Surg*. 2015;99(4):1464-6.
329
- 330 7. Pepper J, Goddard M, Mohiaddin R, Treasure T. Histology of a Marfan aorta 4.5
331 years after personalized external aortic root support. *Eur J Cardiothorac Surg*.
332 2015;48(3):502-5.
333
- 334 8. Van Hoof L, Verbrugge P, Verbeken E, Treasure T, Famaey N, Meuris B, et al.
335 Support of the aortic wall: a histological study in sheep comparing a macroporous mesh
336 with low-porosity vascular graft of the same polyethylene terephthalate material.
337 *Interact Cardiovasc Thorac Surg*. 2017;25(1):89-95.
338
- 339 9. David TE, Feindel CM. An aortic valve-sparing operation for patients with aortic
340 incompetence and aneurysm of the ascending aorta. *J Thorac Cardiovasc Surg*.
341 1992;103(4):617-21.
342
- 343 10. Pye D. *The Nature and Art of Workmanship*: Cambridge University Press; 1968
344 1968.
345
- 346 11. Golesworthy T, Pepper J, Treasure T. ExoVasc® Personalised External Aortic Root Support:
347 INSTRUCTIONS FOR USE 2022 [Available from: <https://discovery.ucl.ac.uk/id/eprint/10154140/>.
348 Exstent. Personalised External Aortic Root Support.
349
- 350 12. Nemec P, Kolarik M, Fila P. Personalized external aortic root support - how to
351 implant it. *Acta Chir Belg*. 2022;122(1):70-3.

352 **

353 This paper revisits the technical details of how exactly to perform the operation. It
354 provides technical tips which the authors have learned the hard way and if studied
355 carefully, and the advice heeded, should hasten the learning experience.(19)

356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404

13. Pepper J, Golesworthy T, Utley M, Chan J, Ganeshalingam S, Lamperth M, et al. Manufacturing and placing a bespoke support for the Marfan aortic root: description of the method and technical results and status at one year for the first ten patients. *Interact Cardiovasc Thorac Surg.* 2010;10(3):360-5.

14. Treasure T, Crowe S, Chan KM, Ranasinghe A, Attia R, Lees B, et al. A method for early evaluation of a recently introduced technology by deriving a comparative group from existing clinical data: a case study in external support of the Marfan aortic root. *BMJ Open.* 2012;2(2):e000725.

15. Allen C, Pepper J. External aortic support for people with Marfan's syndrome. *BMJ.* 2010;340:c1692.

16. Chauvette V, Chamberland ME, El-Hamamsy I. A review of pulmonary autograft external support in the Ross procedure. *Expert Rev Med Devices.* 2019;16(11):981-8.

17. Tanaka D, Mazine A, Ouzounian M, El-Hamamsy I. Supporting the Ross procedure: preserving root physiology while mitigating autograft dilatation. *Curr Opin Cardiol.* 2022;37(2):180-90.

18. Golesworthy T. ExoVasc® Personalised External Aortic Root Support (PEARS) Project Status – 17 January 2022 2022 [Available from: <https://discovery.ucl.ac.uk/id/eprint/10144267/>].

19. Nemec P, Pepper J, Fila P. Personalized external aortic root support. *Interact Cardiovasc*

*

This study published in September 2020 summarise the nature of all 317 PEARS operations from the first in April 200 to March 2020 in 25 centres in 9 countries. Marfan syndrome was the indication in 57%. There was one perioperative death (0.3%) 19 had lived more than 10 years since operation. There are interesting reflective comments on how PEARS technical details and appropriate follow up and surgeon considering adopting this surgery would gain valuable insights. The noted a randomized trial would be hard to realize.(16)

20. Van Hoof L, Rega F, Golesworthy T, Verbrugghe P, Austin C, Takkenberg JJM, et al. Personalised external aortic root support for elective treatment of aortic root dilation in 200 patients. *Heart.* 2021;107(22):1790-5.

**

This reports the first 200 consecutive intention to treat PEARS operations. The median age was 33 years. For 147 Marfan patients the median aortic diameter was 47 mm indicating that cardiac terms were implementing this a truly prophylactic operation the majority having a root aneurysm below the 50 mm.(17)

21. Burke CR, Bavaria J. The personalized external aortic root support procedure: interesting niche or ready for prime time? *Heart.* 2021;107(22):1768-9.

**

405 This editorial gives a carefully considered commentary on PEARS praising the results
406 achieved in the first 200 but sceptical of the general applicability. (18)

407

408 22. Treasure T, King A, Hidalgo LL, Golesworthy T, Pepper J, Takkenberg JJ.
409 Developing a shared decision support framework for aortic root surgery in Marfan
410 syndrome. *Heart*. 2018;104(6):480-6.

411

412 23. Kenny L, Austin C, Golesworthy T, Venugopal P, Alphonso N. Personalized
413 External Aortic Root Support (PEARS) for Aortic Root Aneurysm. *Operative Techniques*
414 *in Thoracic and Cardiovascular Surgery*. 2021;26(2):290-305.

415

416 **

417 A comprehensive account of PEARS including a description of the key principles of
418 patient selection, surgical steps and postoperative care and detailed figures describing
419 the implantation of a PEARS device with complementary video clips.

420

421

422 24. Austin C, Thompson P, Fittipaldi M, Treasure T. The consequences of incomplete
423 covering of the critical part of the aortic root in Personalized External Aortic Root
424 Support. *Eur J Cardiothorac Surg*. 2021;59(5):1095.

425

426 **

427 This is a case report where the surgeon departed from the "Instructions for Use" of a
428 personalised device, cutting off discarding the part of the mesh sleeve intended for
429 aorta between the coronary arteries and the aorto-coronary junction, leaving the root
430 uncovered. As a result the aortic sinuses continued to enlarge and the aortic valve
431 became incompetent. This was "an inadvertent 'double-blind' trial of a sham operation"
432 since neither the patient or colleagues following up the patient were informed.(20)

433

434

435 25. Kim HH, Lee S, Lee SH, Youn YN, Yoo KJ, Joo HC. The long-term fate of ascending
436 aorta aneurysm after wrapping versus replacement. *J Thorac Cardiovasc Surg*. 2021.

437

438 26. Van Hoof L, Rega F, Treasure T, Pepper J. What's in a wrap? *J Thorac Cardiovasc*
439 *Surg*. 2021.

440 *

441 This correspondence challenges a somewhat atavistic report suggesting equivalence of
442 a Robicsek style "wrapping" and root replacement.(21, 22)

443

444 27. Nienaber C, Ernst S, Yuan X. PEARS procedure and the difficulty to provide
445 evidence for its benefits. *European Heart Journal*. 2020;41:4086-8.

446

447 **

448 This essay published in November 2020 went into more detail about whether a
449 controlled trial would be appropriate. It merits reading. The authors examine the
450 essential requirements for randomisation that at a point in time there are two
451 treatments similarly applicable and conclude that "the fundamental basis for an RCT is
452 just not present."(25)

453

454 28. Van Hoof L, Verbrugghe P, Jones E, Humphey J, Janssens S, Famaey N, et al.
455 Understanding the pulmonary autograft remodeling after the Ross procedure: stick to
456 the facts. *Frontiers in Cardiovascular Medicine*. 2022;9(February).

457 **

458 An outstanding analysis of “mechanobiology of the Ross Procedure”. This comes from a
459 team at the University of Leuven which brings together bioengineers, biologists and
460 surgeons who have explored in depth the challenge of the use of the pulmonary
461 autograft in the aortic root and paves the way for its practical implementation.(26)

462

463